Ppt New ^hot^ — Wilms Tumor

Wilms Tumor PPT: New Approaches, Molecular Insights, and 2026 Clinical Updates

Subtitle: A Modern Slide Deck for Pediatric Oncology, Nephrology, and Radiology Teams

Slide 7: Staging (COG System) – Use a Table/Flowchart

| Stage | Description | |-------|-------------| | I | Tumor limited to kidney, completely resected, capsule intact. | | II | Tumor extends beyond kidney but completely resected (no residual). | | III | Residual non-hematogenous tumor post-op (e.g., positive margins, lymph node involvement). | | IV | Hematogenous metastases (lung, liver, bone, brain). | | V | Bilateral renal involvement at diagnosis. | wilms tumor ppt new

Slide 8: Treatment Overview (Risk-Stratified)

• Low/Standard Risk (Favorable histology, Stage I-II): Nephrectomy + short-course chemotherapy (vincristine, dactinomycin).
• High Risk (Stage III-IV or anaplastic): Pre-operative chemotherapy → delayed nephrectomy → intensified therapy (add doxorubicin ± radiation).
• Bilateral Disease (Stage V): Aim for bilateral nephron-sparing surgery after neoadjuvant chemo.

Histologic Types (NWTS-5 classification):

| Type | Favorable (FH) | Unfavorable (UH) | |------|----------------|------------------| | Triphasic (blastema, stroma, epithelium) | Anaplasia (focal or diffuse) | | Prognosis >90% survival | Requires intensified chemo | Wilms Tumor PPT: New Approaches, Molecular Insights, and

Prognosis

The prognosis for children with Wilms tumor is generally good, with a 5-year survival rate of about 90%. However, the prognosis depends on the stage of the disease at diagnosis and the response to treatment. Histologic Types (NWTS-5 classification): | Type | Favorable

Slide-by-Slide Outline of the New PPT

• Slide 3-4: Epidemiology & Etiology – Age peak (2-5 years), incidence, racial predilection, and genetic syndromes.
• Slide 5-7: Pathology – Classic triphasic histology (blastemal, stromal, epithelial components), anaplasia (favorable vs. unfavorable histology), and molecular markers.
• Slide 8-10: Clinical Presentation – Common signs: asymptomatic abdominal mass, hematuria, hypertension, and fever. Paraneoplastic syndromes.
• Slide 11-13: Diagnostic Workup – Imaging (Ultrasound first, then CT chest/abdomen), lab findings (Nephroblastomatosis), and staging (Stage I-V).
• Slide 14-16: Treatment Protocols (New Emphasis) – A side-by-side comparison table of COG (upfront surgery) vs. SIOP (pre-op chemotherapy). Discussion of nephron-sparing surgery for bilateral disease.
• Slide 17-19: Risk-Based Therapy – Detailed algorithm: Low-risk (Stage I favorable histology → surgery + 2 drugs) vs. High-risk (Stage IV anaplastic → surgery + 3 drugs + radiation).
• Slide 20-21: Novel & Emerging Therapies – Role of targeted therapy (e.g., BET inhibitors, IGF-1R inhibitors) and reduced radiation fields in current trials (e.g., AREN1721).
• Slide 22-23: Prognosis & Outcomes – Excellent survival (>90% for localized disease), poor prognostic factors (diffuse anaplasia, stage IV, relapse <6 months).
• Slide 24-25: Late Effects & Survivorship – Cardiac toxicity (doxorubicin), secondary malignancies, renal insufficiency, and fertility preservation.
• Slide 26-27: Case Studies – Two interactive cases: (1) Unilateral favorable histology, (2) Bilateral Wilms Tumor with syndromic features.
• Slide 28-30: Summary & Key Takeaways – One-page algorithm, top 10 pearls, and a reference list with 2024-2025 COG/SIOP updates.

Slide 12: Case-Based Discussion (Interactive PPT Slide)

Include a 2-minute case to engage your audience:

3-year-old girl with right renal mass. CT shows tumor thrombus in IVC below diaphragm. No metastases. Biopsy shows favorable histology. Molecular panel: 1q gain. How do you treat?

Answer per new guidelines: Stage III (tumor thrombus) + molecular high-risk → intensify to Regimen DD-4A + flank radiation (19.8 Gy) despite favorable histology.